104 related articles for article (PubMed ID: 22840383)
1. Midterm follow-up after DC-BEAD™-TACE of hepatocellular carcinoma (HCC).
Skowasch M; Schneider J; Otto G; Weinmann A; Woerns MA; Dueber C; Pitton MB
Eur J Radiol; 2012 Dec; 81(12):3857-61. PubMed ID: 22840383
[TBL] [Abstract][Full Text] [Related]
2. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
3. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead.
Malagari K; Alexopoulou E; Chatzimichail K; Hall B; Koskinas J; Ryan S; Gallardo E; Kelekis A; Gouliamos A; Kelekis D
Abdom Imaging; 2008; 33(5):512-9. PubMed ID: 17938995
[TBL] [Abstract][Full Text] [Related]
4. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization.
Sadick M; Haas S; Loehr M; Elshwi M; Singer MV; Brade J; Schoenberg SO; Diehl SJ
Onkologie; 2010; 33(1-2):31-7. PubMed ID: 20164659
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients.
Malagari K; Pomoni M; Spyridopoulos TN; Moschouris H; Kelekis A; Dourakis S; Alexopoulou E; Koskinas J; Angelopoulos M; Kornezos J; Pomoni A; Tandeles S; Marinis A; Rizos S; Kelekis D
Cardiovasc Intervent Radiol; 2011 Aug; 34(4):774-85. PubMed ID: 21184228
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.
Kalva SP; Pectasides M; Yeddula K; Ganguli S; Blaszkowsky LS; Zhu AX
J Vasc Interv Radiol; 2013 Feb; 24(2):257-65. PubMed ID: 23369560
[TBL] [Abstract][Full Text] [Related]
7. Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol.
Recchia F; Passalacqua G; Filauri P; Doddi M; Boscarato P; Candeloro G; Necozione S; Desideri G; Rea S
Oncol Rep; 2012 May; 27(5):1377-83. PubMed ID: 22294036
[TBL] [Abstract][Full Text] [Related]
8. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
9. Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisation using drug-eluting beads: a pilot study focused on sustained tumor necrosis.
Moschouris H; Malagari K; Papadaki MG; Kornezos I; Matsaidonis D
Cardiovasc Intervent Radiol; 2010 Oct; 33(5):1022-7. PubMed ID: 20101403
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.
Chung GE; Lee JH; Kim HY; Hwang SY; Kim JS; Chung JW; Yoon JH; Lee HS; Kim YJ
Radiology; 2011 Feb; 258(2):627-34. PubMed ID: 21273524
[TBL] [Abstract][Full Text] [Related]
12. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
[TBL] [Abstract][Full Text] [Related]
13. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
[TBL] [Abstract][Full Text] [Related]
15. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
16. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation.
Bargellini I; Vignali C; Cioni R; Petruzzi P; Cicorelli A; Campani D; De Simone P; Filipponi F; Bartolozzi C
Radiology; 2010 Apr; 255(1):289-300. PubMed ID: 20308465
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST.
Syha R; Ketelsen D; Heller S; Schmehl J; Mangold S; Heuschmid M; Springer F; Claussen CD; Brechtel K
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1325-32. PubMed ID: 22872074
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma.
Hoffmann R; Rempp H; Syha R; Ketelsen D; Pereira PL; Claussen CD; Clasen S
Eur J Radiol; 2014 Oct; 83(10):1793-8. PubMed ID: 25052871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
